| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 59.59% | Raymond James | → $2.5 | Downgrades | Outperform → Market Perform |
| 11/14/2023 | 59.59% | Raymond James | → $2.5 | Downgrades | Outperform → Market Perform |
| 11/09/2023 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/05/2023 | -20.2% | Goldman Sachs | $3 → $1.25 | Maintains | Sell |
| 06/02/2023 | -20.2% | Goldman Sachs | $3 → $1.25 | Downgrades | Neutral → Sell |
| 05/11/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 11/29/2022 | 283.02% | Berenberg | → $6 | Initiates Coverage On | → Buy |
| 10/04/2022 | 219.18% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
| 08/16/2022 | 283.02% | BTIG | $5 → $6 | Maintains | Buy |
| 08/16/2022 | 825.63% | Raymond James | $11.5 → $14.5 | Maintains | Outperform |
| 06/16/2022 | 177.69% | Jefferies | $11.5 → $4.35 | Maintains | Buy |
| 05/18/2022 | 91.51% | B of A Securities | $6 → $3 | Downgrades | Neutral → Underperform |
| 03/02/2022 | 666.04% | Cowen & Co. | → $12 | Initiates Coverage On | → Outperform |
| 02/23/2022 | 346.86% | Goldman Sachs | → $7 | Initiates Coverage On | → Neutral |
| 02/01/2022 | 283.02% | B of A Securities | → $6 | Initiates Coverage On | → Neutral |
| 01/28/2022 | 410.69% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
| 01/07/2022 | 666.04% | BTIG | → $12 | Initiates Coverage On | → Buy |
| 10/13/2021 | 825.63% | Raymond James | → $14.5 | Initiates Coverage On | → Outperform |
| 10/12/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 09/20/2021 | 793.71% | HSBC | → $14 | Initiates Coverage On | → Buy |
What is the target price for Ginkgo Bioworks Holdings (DNA)?
The latest price target for Ginkgo Bioworks Holdings (NYSE: DNA) was reported by Raymond James on November 15, 2023. The analyst firm set a price target for $2.50 expecting DNA to rise to within 12 months (a possible 59.59% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ginkgo Bioworks Holdings (DNA)?
The latest analyst rating for Ginkgo Bioworks Holdings (NYSE: DNA) was provided by Raymond James, and Ginkgo Bioworks Holdings downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for Ginkgo Bioworks Holdings (DNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ginkgo Bioworks Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ginkgo Bioworks Holdings was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Ginkgo Bioworks Holdings (DNA) correct?
While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a downgraded with a price target of $0.00 to $2.50. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.57, which is within the analyst's predicted range.